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Introduction: The steady increase in the incidence of obesity among adults has been paralleled with higher
levels of obesity-associated breast cancer. While recent studies have suggested that adipose stromal/stem cells
(ASCs) isolated from obese women enhance tumorigenicity, the mechanism(s) by which this occurs remains
undefined. Evidence suggests that increased adiposity results in increased leptin secretion from adipose tissue,
which has been shown to increased cancer cell proliferation. Previously, our group demonstrated that ASCs
isolated from obese women (obASCs) also express higher levels of leptin relative to ASCs isolated from lean
women (lnASCs) and that this obASC-derived leptin may account for enhanced breast cancer cell growth. The
current study investigates the impact of inhibiting leptin expression in lnASCs and obASCs on breast cancer cell
(BCC) growth and progression.
Methods: Estrogen receptor positive (ER+) BCCs were co-cultured with leptin shRNA lnASCs or leptin shRNA obASCs
and changes in the proliferation, migration, invasion, and gene expression of BCCs were investigated. To assess the direct
impact of leptin inhibition in obASCs on BCC proliferation, MCF7 cells were injected alone or mixed with control shRNA
obASCs or leptin shRNA obASCs into SCID/beige mice.
Results: ER+ BCCs were responsive to obASCs during direct co-culture, whereas lnASCs were unable to
increase ER+ BCC growth. shRNA silencing of leptin in obASCs negated the enhanced proliferative effects of
obASC on BCCs following direct co-culture. BCCs co-cultured with obASCs demonstrated enhanced expression
of epithelial-to-mesenchymal transition (EMT) and metastasis genes (SERPINE1, MMP-2, and IL-6), while BCCs
co-cultured with leptin shRNA obASCs did not display similar levels of gene induction. Knockdown of leptin
significantly reduced tumor volume and decreased the number of metastatic lesions to the lung and liver.
These results correlated with reduced expression of both SERPINE1 and MMP-2 in tumors formed with MCF7
cells mixed with leptin shRNA obASCs, when compared to tumors formed with MCF7 cells mixed with
control shRNA obASCs.
Conclusion: This study provides mechanistic insight as to how obesity enhances the proliferation and
metastasis of breast cancer cells; specifically, obASC-derived leptin contributes to the aggressiveness of breast
cancer in obese women.* Correspondence: bbunnell@tulane.edu
1Center for Stem Cell Research and Regenerative Medicine, Tulane University
School of Medicine, 1430 Tulane Avenue, SL-99, New Orleans, LA 70112, USA
4Department of Pharmacology, Tulane University School of Medicine, New
Orleans, LA 70112, USA
Full list of author information is available at the end of the article
© 2015 Strong et al. Open Access This artic
International License (http://creativecommo
reproduction in any medium, provided you
link to the Creative Commons license, and
Dedication waiver (http://creativecommons
article, unless otherwise stated.le is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Strong et al. Breast Cancer Research  (2015) 17:112 Page 2 of 16Introduction
Obesity is defined by the accumulation of excessive
adipose tissue that can contribute to physical and psy-
chosocial impairment. The prevalence of obesity in the
world, particularly in the USA, has increased over the
past four decades, with one third of adults in the USA
meeting the criteria for obesity [1]. As a result, there has
been an increase in the incidence of obesity-associated
cancers [2–4]. More specifically, recent studies suggest
that obesity increases the incidence of breast cancer [5, 6].
Epidemiological studies investigating the role of obes-
ity in breast cancer suggest that obesity increases the
incidence of metastatic breast tumors, results in higher
rates of incidence of recurrence, and increases mortality.
Haakinson et al. found that obese patients are diagnosed
with larger primary tumors and had increased incidence
of lymph node metastases [7]. Furthermore, in postmen-
opausal breast cancer patients, up to 50 % of deaths have
been attributed to obesity [8]. While the link between
obesity and breast cancer has been well-documented
from epidemiologic analyses, the molecular mechanisms
underlying this correlation are not fully defined.
An analysis of the interplay between breast cancer and
obesity provides some insights into the underlying
pathophysiology. During breast cancer development and
progression, a complex multi-step cascade converts nor-
mal breast epithelial cells into malignant cells [9–11].
One of the key steps involves the interaction between
the epithelial cells and the stromal microenvironment,
which contains adipose stromal/stem cells (ASCs) [12].
Studies have shown that obesity significantly increases
the number of ASCs within the adipose tissue. This ASC
hyperplasia has been shown to support both angiogen-
esis and adipogenesis and to alter the gene expression
profile of ASCs such that they enhance cancer growth
[13–15]. Recently, our group has demonstrated that ASCs
isolated from obese patients with body mass index (BMI)
≥30 (obASCs) enhance the tumorigenicity MCF7 breast
cancer cells, and alter their gene expression profile [13].
Additionally, the data showed that the obASCs expressed
significantly higher levels of leptin compared to ASCs iso-
lated from lean patients with BMI ≤25 (lnASCs). However,
the overexpression of leptin in obASCs and the impact it
has on increasing the aggressiveness of tumor cell biology
in vitro and in vivo has not been investigated.
The role of leptin produced by obASCs on breast
cancer cells (BCCs) was investigated in this study by
inhibiting the expression of leptin using a short hairpin
RNA (shRNA) knockdown strategy. The obASCs prefer-
entially increased the proliferation, migration, and inva-
sion of several estrogen receptor positive (ER+) BCC
lines, including MCF7, ZR75, and T47D, during direct
co-culture. Reducing the levels of leptin in obASCs ne-
gated their effects on BCCs. Consistent with phenotypicchanges, inhibiting leptin expression in obASCs negated
alterations to the gene expression profile of BCC after
co-culture. Furthermore, reducing leptin levels in obASCs
also resulted in a reduction in tumor volume and fewer
metastatic lesions in the lung and liver of SCID/beige
mice. These results implicate obASC-derived leptin as a
key mechanism that alters BCC growth and supports
changes to the biology of BCCs into a more aggressive
phenotype. The results here suggest that the inhibition of
leptin secreted by obASCs may result in reduced tumor
volume and metastasis to distant organs, reducing the bur-
den of obesity-associated breast cancers.
Methods
Human subjects
Human ASCs were obtained from 12 Caucasian women
(two groups, six donors per group) undergoing elective
liposuction procedures, as previously described [16]. All
protocols were reviewed and approved by the Pennington
Biomedical Research Center Institutional Review Board,
and all human participants provided written informed con-
sent. Briefly, ASCs were isolated from processed liposuc-
tion aspirates from the subcutaneous abdominal adipose
tissue of lean or obese patients. Liposuction aspirates were
incubated in 0.1 % type I collagenase (Sigma , St. Louis,
MO) and 1 % powdered bovine serum albumin (BSA, frac-
tion V; Sigma) dissolved in 100 ml of PBS supplemented
with 2 mM calcium chloride. The mixture was placed in a
37 °C shaking water-bath or incubator at 75 rpm for 60 mi-
nutes and then centrifuged to remove oil, fat, primary adi-
pocytes, collagenase solution and cellular debris. The
resulting cell pellet was re-suspended in stromal medium
(SM), which consisted of DMEM/F12 (Hyclone, Logan,
UT, USA), 10 % FBS (Hyclone), 1 % antibiotic/antimycotic
(Fisher Scientific, Houston, TX, USA), and plated in 175-
cm2 flasks. Fresh SM was added every 2–3 days until cells
achieved 80–90 % confluence, at which time cells were
harvested with 0.25 % trypsin/1 mM EDTA (GIBCO,
Grand Island, NY, USA) and cryopreserved prior to experi-
mental use. The mean BMI for the lnASC group was 22.7
± 1.9, while the mean BMI for the obASCs was 32.7 ± 3.7.
The mean age of the subjects for each group of donors was
as follows: lnASCs (38.8 ± 7.0 years) and obASCs (42.5 ±
8.9 years). There was no statistically significant difference
in age between the donor groups.
Cell culture
ASCs
Frozen vials of ASCs were thawed and cultured on
150-cm2 culture dishes (Nunc, Rochester, NY, USA)
in 25 ml of complete culture medium (CCM) and in-
cubated at 37 °C with 5 % humidified CO2. After 24
hours, viable cells were harvested with 0.25 % tryp-
sin/1 mM EDTA and re-plated at 100–200 cells/cm2
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Medium (αMEM; GIBCO), 20 % FBS (Atlanta Biolog-
icals, Lawrenceville, GA, USA), 100 units per ml peni-
cillin/100 μg/ml streptomycin (P/S; GIBCO), and 2 mM L-
glutamine (GIBCO). Medium was changed every 2–3 days.
For all experiments, sub-confluent cells (≤70 % confluent)
between passages 2–6 were used. Characterization of stem
cells has previously been performed and published [13].
Breast cancer cell (BCC) lines
MCF7 (HTB-22), ZR75 (CRL-1500), and T47D (HTB-
133) cells were obtained directly from American Type
Culture Collection (ATCC; Manassas, VA, USA) and
used within 6 months of resuscitation. Cell line authen-
tication was conducted by ATCC via short tandem re-
peat profiling. Cells were cultured in DMEM (GIBCO),
supplemented with 10 % FBS (Atlanta Biologicals) and
P/S. Cells were grown at 37 °C with 5 % humidified
CO2, fed every 2–3 days, and split 1:4 to 1:6 when the
cells reached 90 % confluence.
Synthesis of green fluorescent protein positive (GFP+)
BCCs
To produce lentivirus, 293T cells were transfected
through a modified calcium chloride transfection proto-
col when cells reached 70−75 % confluence. For each
transfection, 10 μg of packaging plasmid, enveloping en-
coding plasmid, and transfer plasmid containing GFP
and neomycin resistance or dsRed and neomycin resist-
ance were used. After 48 hours, medium was harvested
and used to transduce cancer cells. To transduce ASCs,
conditioned medium containing virus with dsRed and
neomycin resistance was added to ASCs at 70 % conflu-
ence. MCF7, ZR75, T47D, and ASCs were selected with
500 μg/ml of Geneticin (Invitrogen; Carlsbad, CA, USA)
for 2 weeks and GFP expression or dsRed expression
was verified with flow cytometry. All cancer cells and
ASCs used for experimentation expressed GFP or dsRed
unless otherwise specified.
Conditioned media
ASCs pooled from six donors per group, were plated on
a 150-cm2 cell culture dish at 100 cells/cm2. After over-
night culture, medium was replaced with serum-free
αMEM. After 7 days, conditioned media (CM) were col-
lected and filtered to remove cellular debris. The total
number of ASCs was also counted to verify equal num-
ber of cells after 7 days. ASC CM from lnASCs and
obASCs was plated on top of BCCs set up in triplicates.
After 7 days, the total number of MCF7 cells was counted.
Where indicated, CM was collected from control shRNA
lnASCs, leptin shRNA lnASCs, control shRNA obASCs,
and leptin shRNA obASCs.Stable transfection of shRNA
shRNA constructs targeting leptin and an shRNA con-
struct targeting a non-human gene serving as a negative
control were purchased from SA Biosciences (Frederick,
MD, USA). The GFP sequence in the shRNA construct
was removed and replaced with dsRed and neomycin re-
sistance, producing a dsRed, neomycin-resistant leptin
shRNA construct and a dsRed, neomycin-resistant nega-
tive control shRNA construct. The lnASCs (n = 6 donors)
and obASCs (n = 6 donors) were transfected with a dsRed,
neomycin-resistant leptin shRNA construct or a dsRed,
neomycin-resistant negative control shRNA construct
using the Neon Transfection System (Invitrogen), using
1400 V for the pulse voltage, 10 ms for the pulse width,
and three pulses. Cells were allowed to recover, expanded,
underwent antibiotic selection for 2 weeks, and sorted by
flow cytometry to verify dsRed expression. Four groups of
cells (n = 6 donors/group) were produced: control shRNA
lnASCs, leptin shRNA lnASCs, control shRNA obASCs,
and leptin shRNA obASCs.
Alamar blue cell proliferation assay
Alamar blue cell proliferation assay was conducted ac-
cording to manufacturer’s instructions. Briefly, 100 cells
from each donor (lnASCs, control shRNA lnASCs, lep-
tin shRNA lnASCs, obASCs, control shRNA obASCs,
or leptin shRNA obASCs) were plated in a 96-well plate
in triplicates. After cells had adhered overnight, the
medium was removed, the wells were washed three
times in PBS, and the cells were incubated in 10 %
Alamar Blue reagent (Invitrogen). After 18 hours, the
fluorescence intensity was measured at an excitation
wavelength of 540 nm and an emission wavelength of
580 nm using a fluorescence plate reader. Cells were
assessed on days 1, 3, and 7.
RNA isolation followed by reverse transcriptase
polymerase chain reaction (qRT-PCR)
Subconfluent cultures of control shRNA lnASCs (n = 6
donors), leptin shRNA lnASCs (n = 6 donors), control
shRNA obASCs (n = 6 donors), and leptin shRNA
obASCs (n = 6 donors) were analyzed. RNA was extracted
from ASCs using TRIzol reagent (Invitrogen), purified
with RNeasy columns (Qiagen, Valencia, CA, USA), and
digested with DNase I (Invitrogen). A total of 1 μg of
cellular RNA was used for cDNA synthesis with
SuperScript VILO cDNA synthesis kit (Invitrogen).
Quantitative real-time PCR was performed using the
EXPRESS SYBR GreenER qPCR SuperMix Kit (Invitro-
gen) according to the manufacturer’s instructions. The
following primer set sequence for leptin (forward 5′
-gaagaccacatccacacacg-3′, reverse 5′-agctcagccagacc-
catcta-3′) and β-actin (forward 5′-caccttctacaatgagctgc-3′
and reverse 5′-tcttctcgatgctcgacgga-3′) were used. At the
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was calculated to quantify mRNA expression.
Characterization of ASCs
ASCs were characterized as previously described [17].
Briefly, ASCs were induced to undergo osteogenic or
adipogenic differentiation. For osteogenic differentiation,
ASCs were cultured in 6-well plates in CCM until 70 %
confluent and medium was replaced with fresh medium
containing osteogenic supplements, consisting of 50 μM
ascorbate 2-phosphate (Sigma), 10 mM β-glycerol phos-
phate (Sigma), and 10 nM dexamethasone. After 3 weeks,
cells were fixed in 10 % formalin for 1 hour at 4 °C and
stained for 10 minutes with 40 mM Alizarin Red (pH 4.1;
Sigma) to visualize calcium deposition in the extracellular
matrix. Images were acquired at × 4 magnification using
the Nikon Eclipse TE200 (Melville, NY, USA) with the
Nikon Digital Camera DXM1200F and the Nikon ACT-1
software version 2.7. For adipogenic differentiation, ASCs
were cultured in 6-well plates in CCM until 70 % conflu-
ent, and medium was replaced with fresh medium con-
taining adipogenic supplements consisting of 0.5 μM
dexamethasone (Sigma), 0.5 mM isobutylmethylxanthine
(Sigma), and 50 μM indomethacin (Sigma). After three
weeks, cells were fixed in 10 % formalin for 1 hour at 4 °C,
stained for 10–15 minutes at room temperature with Oil
Red O (Sigma) to detect neutral lipid vacuoles, and images
were acquired at × 10 magnification.
To determine the ability to form colony-forming units
(CFU), ASCs were plated at a density of 100 cells on a
10-cm2 plate in CCM and incubated for 14 days. Plates
were rinsed three times with PBS, and 10 ml of 3 %
crystal violet (Sigma) was added for 30 minutes at room
temperature. Plates were washed three times with PBS
and once with tap water.
Analysis by flow cytometry of the cell surface marker
profile was conducted by harvesting ASCs with 0.25 %
trypsin/1 mM EDTA for 3–4 minutes at 37 °C. A total
of 3 × 105 cells were concentrated by centrifugation at
500 × g for 5 minutes, suspended in 50 μl PBS and la-
beled with the primary antibodies. The following
primary antibodies were used: anti-CD45-PeCy7, anti-
CD11b-PeCy5, anti-CD166-PE, anti-CD105-PE, anti-
CD90-PeCy5, anti-CD34-PE, isotype-control fluorescein
isothiocyanate (FITC) human IgG1 and isotype-control
PE human IgG2a were purchased from Beckman Coulter
(Indianapolis, IN, USA). Anti-CD44-APC was purchased
from BD Biosciences (Franklin Lakes, NJ, USA). The
samples were incubated for 30 minutes at room
temperature, washed with PBS, and analyzed with the
Galios Flow Cytometer (Beckman Coulter, Brea, CA,
USA), running Kaluza software (Beckman Coulter). To
assay cells by forward and side scatter of light, the FACS-
can was standardized with microbeads (Dynosphereuniform microspheres, Bangs Laboratories Inc., Thermo
Scientific, Waltham, MA, USA). At least 10,000 events
were analyzed and compared with isotype controls.
BCC and ASC co-culture
BCCs were co-cultured with lnASCs (n = 6 donors) or
obASCs (n = 6 donors) at 200 cells/cm2 in a 1:1 ratio in
DMEM supplemented with 10 % FBS (Atlanta Biologicals)
and P/S. After 7 days, cells were harvested, washed, and
analyzed by flow cytometry. The percentage of GFP+ cells
(BCCs) was determined using the Galios Flow Cytometer,
running Kaluza software, and calculated based on the total
number of cells. Where indicated, control shRNA lnASCs
(n = 6 donors), leptin shRNA lnASCs (n = 6 donors), con-
trol shRNA obASCs (n = 6 donors), and leptin shRNA
obASCs (n = 6 donors) were co-cultured with MCF7,
ZR75, or T47D for 7 days. The percentage of GFP+ cells
(BCCs) was determined with the Galios Flow Cytometer,
running Kaluza software, and calculated based on the total
number of cells. For RNA isolation, BCCs were sorted after
co-culture with the Becton-Dickinson FACSVantage SE
Cell Sorter with the DiVa option (BD, Franklin Lakes, NJ,
USA) and analyzed with the DiVa software v5.02 (BD).
Transwell migration and invasion assays
Migration assays were performed in transwell inserts
with 8-μm-pore membrane filters, while invasion assays
were performed with 8-μm transwell inserts pre-coated
with a growth factor-reduced Matrigel layer to mimic
basement membranes (BD Biosciences). BCC cells were
cultured alone or co-cultured with control lnASCs, lep-
tin shRNA lnASCs, control obASCs, or leptin shRNA
obASCs for 7 days in a 1:1 ratio. BCCs were purified
with FACS, and 1.25 × 104 BCCs suspended in 50 μl
were added to the apical chamber. A total of 200 μl of
chemoattractant (10 % FBS; Atlanta Biologicals) was
added to the basal chamber and incubated for 4 hours
or 24 hours for migration or invasion, respectively. After
the allotted time, the lower side of the transwell insert was
carefully washed with cold PBS and non-migrating or non-
invading cells remaining on the top chamber were re-
moved with a cotton tip applicator. Migrating and invading
cells were stained with Calcein-AM (2 μg/ml; Invitrogen)
and measured on a fluorescent plate reader (FLUOstar op-
tima, BMG Labtech Inc., Durham, NC, USA). Data were
normalized to the respective BCCs without previous ex-
posure to ASCs.
RNA isolation followed by custom RT2 Profiler™ PCR
arrays
To assess cells with the PCR array, total cellular RNA
was extracted using RNeasy Mini Kit from FACS-
purified BCCs cultured alone or after co-culture with a
pool of control shRNA lnASCs, leptin shRNA lnASCs,
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six donors per group (Qiagen). RNA was treated with
DNase I (Qiagen) according to manufacturer’s instruc-
tions: 1 μg of RNA was converted to cDNA with the
RT2 First Strand Kit (SA Biosciences) according to the
manufacturer’s protocol. Where indicated, total cellular
RNA was extracted from tumors using RNeasy Mini Kit,
treated with DNase I, and converted to cDNA with the
RT2 First Strand Kit according to the manufacturer’s in-
structions. Gene expression profiling was performed
using a Custom Breast Cancer RT2 Profiler PCR Array
(SA Biosciences) and RT2 qPCR Master Mix (SA Biosci-
ences). The Custom Breast Cancer RT2 Profiler PCR
Array was manufactured to detect the expression of the
following genes: SERPINE1, IGFBP3, GSTP1, MMP-2,
SNAI2, IL-6, PGR, TWIST1, PTGS2, SFRP1, THBS1,
CDKN2A, PLAU, CSF1, and ACTB. PCR amplification
was performed in a Bio-Rad CFX96 Real-Time System
(Hercules, CA, USA). The reaction conditions were as
follows: 95 °C for 10 minutes, 40 cycles of 95 °C for 15
sec and 60 °C for 1 minute, followed by a dissociation
curve. At the completion of the reaction, Ct values were
determined, and ΔΔ Ct and fold change were deter-
mined using the RT2 Profiler PCR Array Data Analysis
web portal (SA Biosciences). Genes with mRNA levels
increased or decreased more than two-fold were consid-
ered significantly differentially expressed (P <0.05).
In vivo tumorigenicity assay
SCID/beige (CB17.Cg-PrkdcscidLystbg-J/Crl) immuno-
compromised female ovariectomized mice (5 weeks
old) were obtained from Charles River Laboratories
(Wilmington, MA, USA). To assess whether leptin im-
pacts tumorigenicity, mice were divided into three
groups (n = 5 mice/group): MCF7 cells only, MCF7
cells plus control shRNA obASCs (n = 6 donors), and
MCF7 plus leptin shRNA obASCs (n = 6 donors). Es-
tradiol pellets (0.72 mg, 60-day release, Innovative
Research of America, Sarasota, FL, USA) were im-
planted subcutaneously in the lateral area of the neck.
Cell implants were prepared with MCF7 cells (106)
alone or MCF7 cells (106) in combination with ASCs
(106) suspended in a total volume of 150 μl (one part
sterile PBS and two parts reduced growth factor
Matrigel (BD Biosciences). Cells were injected subcuta-
neously into the fifth mammary fat pad on both sides.
All procedures in animals were carried out under
anesthesia using a mixture of isoflurane and oxygen de-
livered continuously by mask. After 36 days, animals
were euthanized by cervical dislocation after exposure
to CO2. Organs were removed, weighed, digitally im-
aged, and fixed in 10 % neutral buffered formalin.
Where indicated, additional mice were divided into
three groups (n = 5 mice/group): MCF7 only, MCF7plus lnASCs, and MCF7 plus obASCs to assess for po-
tential metastasis by lnASCs or obASCs. Lungs and
livers were also harvested and fixed in 10 % neutral
buffered formalin for histological analyses.
All procedures involving animals were conducted in
compliance with State and Federal law, standards of the
US Department of Health and Human Services, and guide-
lines established by Tulane University Institutional Animal
Care and Use Committee (IACUC). All animal protocols
were approved by the Tulane University IACUC.Flow cytometry
Flow cytometry was conducted on the tumors to assess
for GFP expressing MCF7 cells and dsRed expressing
ASCs. Tumors were dissociated with collagenase/hyal-
uronidase (Stem Cell Technologies, Vancouver, BC,
Canada) for 16 hours at 37 °C. After enzymatic dissoci-
ation, the reaction was neutralized with pre-warmed
medium consisting of 10 % FBS (Atlanta Biologicals).
Cells were centrifuged at 350 × g for 10 minutes,
counted, and resuspended in PBS. The samples were
then analyzed with the Galios Flow Cytometer running
Kaluza software.Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) tumor, lung,
and liver sections were de-paraffinized, rehydrated in
Sub-X (Leica, Buffalo Grove, IL, USA) and graded solu-
tions of ethanol, and stained with hematoxylin and
eosin. FFPE tumor sections were de-paraffinized, rehy-
drated in Sub-X and graded solutions of ethanol,
quenched with 0.3 % H2O2 (Sigma), rinsed with Tris-
NaCl-Tween buffer (TNT), which consisted of 0.1 M
Tris-HCl (pH 7.5; Sigma), 0.15M NaCl (Sigma), and
0.05 % Tween-20 (Invitrogen). Tumor sections were
then blocked with 1 % BSA, and stained with primary
antibodies obtained from Abcam against GFP, dsRed,
SERPINE1, or matrix metalloproteinase-2 (MMP-2)
overnight at 4 °C. Each tumor section was subsequently
washed in TNT buffer. Tissue sections were incubated
with appropriate horseradish peroxidase (HRP)-conju-
gated secondary antibody (Abcam) for 1 hour at room
temperature, and washed with TNT buffer. For colori-
metric staining, slides were then incubated in 3,3′-Di-
aminobenzidine (DAB; Vector Laboratories), washed
with TNT, counterstained with hematoxylin (Thermo
Scientific), and rinsed with deionized water. Slides were
dehydrated in graded solutions of ethanol, followed by
SubX in the final step, and sealed with Permount
Mounting Medium (Sigma). After staining, images were
acquired at × 10 and × 40 magnification with the Scan-
Scope CS2 (Aperio, Vista, CA, USA).
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Protein lysates were isolated with radioimmunoprecipi-
tation assay (RIPA) buffer (Pierce; Thermo Scientific)
from primary tumors formed with MCF7 cells, MCF7
cells mixed with control shRNA obASCs, or MCF7 cells
mixed with leptin shRNA obASCs. Tumors were ho-
mogenized in RIPA buffer for 5 minutes, and the cell
lysate was clarified by centrifugation at 15,000 × g for 15
minutes. Protein concentration was determined by the
BCA Protein Assay (Pierce). Lysate (20 μg) was resolved on
4−12 % SDS-polyacrylamide gels and transferred to nitro-
cellulose membranes (Invitrogen). Blots were blocked with
blØk Noise Canceling Reagents (Millipore Billerica, MA,
USA). Blots were then incubated with anti-leptin antibody
(R&D Systems; Minneapolis, MN, USA) overnight at 4 °C
and washed with PBS with Tween 20 three times before be-
ing incubated with species-specific IgG conjugated to HRP
for 1 hour at room temperature. Antigen-antibody com-
plexes were visualized after incubation in chemilumines-
cence reagent (Invitrogen). Blots were imaged on an
ImageQuant LAS 4000 (GE Healthcare Life Sciences; Pis-
cataway, NJ, USA) and quantitative analysis of western blots
was performed with densitometry.
Metastasis assessment
Metastatic lesions were quantified by determining the
area occupied by the lesion divided by the total area of
the tissue section. The percentage the tissue occupied by
metastatic cells in the liver and lung were averaged to-
gether for each mouse (n = 5 mice/group) and repre-
sented as the metastatic index.
Statistical analysis
All values are presented as means ± standard error of
the mean (SEM). The statistical differences among
three or more groups were determined by analysis of
variance (ANOVA), followed by post-hoc Tukey mul-
tiple comparison tests versus the respective control
group. Statistical significance was set at P <0.05. Ana-
lysis was performed using Prism (Graphpad Software,
San Diego, CA, USA).
Results
obASCs enhance ER+ BCC proliferation
The impact of ASCs on BCC growth was investigated
using a co-culture assay. BCC lines MCF7, ZR75, and
T47D were cultured alone or at a 1:1 ratio with either
lnASCs or obASCs for 7 days. Prior to co-culture, BCCs
were transduced with lentivirus expressing GFP in order to
isolate BCCs expressing the fluorochrome following the
co-culture period. obASCs increased the proliferation of
ER+ BCCs to 2.0 ± 0.2 fold in MCF7 cells, 2.2 ± 0.1 fold in
ZR75, and 1.9 ± 0.1 fold in T47D (P <0.05; Fig. 1a). While
lnASCs increased the proliferation of ER+ BCCs, the effectwas not as robust and was not statistically significant
(Fig. 1a). These results suggest that ASCs increase the pro-
liferation of all BCCs; however, obASCs markedly in-
creased the proliferation of ER+ BCCs over lnASCs.
Previously, our group demonstrated that obASCs pro-
duce high levels of the adipokine leptin. As aromatase is
a downstream target of leptin, to investigate whether the
effects of leptin were through increased aromatase activ-
ity, we determined the level of aromatase expression in
lnASCs and obASCs and the effects of aromatase inhibi-
tor on our system. The mRNA expression of aromatase
was 12.1-fold and 30.4-fold higher in lnASCs and obASCs,
respectively, compared to MCF7 cells (P <0.05; Fig. 1b).
There was no significant difference in aromatase expres-
sion in cancer cells (Fig. 1b). To assess the functional ac-
tivity of aromatase in our system, we collected CM from
ASCs treated with vehicle or letrozole. CM collected from
vehicle-treated obASCs induced proliferation of MCF7
cells (by 53.4 %), ZR75 cells (by 83.9 %) and T47D cells
(by 65.2 %; P <0.05; Fig. 1c). Upon treatment with CM col-
lected from lnASCs and obASCs treated with letrozole, a
reduction in cancer cell number was observed; however,
cancer cells exposed to CM from obASCs treated with
letrozole were still able to induced BCC proliferation.
These results suggest that while aromatase produced by
obASCs may contribute to increased proliferation of can-
cer cells, alternative pathways activated by leptin may be
driving the effects of obASCs on BCCs proliferation. Fur-
thermore, to determine whether leptin secreted by
obASCs alone enhances breast cancer cell proliferation,
CM from lnASCs and obASCs treated with leptin neutral-
izing antibody were exposed to BCCs. CM from obASCs
treated with leptin neutralizing antibody displayed reduced
proliferative potential on BCCs (1.0 × 106 in MCF7 cells,
0.7 × 106 in ZR75 cells, and 0.8 × 106 in T47D cells), com-
pared to CM from obASCs treated with vehicle (1.6 × 106
in MCF7 cells, 1.1 × 106 in ZR75 cells, and 1.4 × 106 in
T47D cells; Fig. 1d). CM from lnASCs treated with vehicle
or leptin neutralizing antibody demonstrated similar re-
sults (Fig. 1d). Collectively, these results indicate that lep-
tin plays a significant role in increasing BCC proliferation
and indicate that leptin alone in this system enhances the
proliferation of BCCs.
obASCs expressing leptin shRNA have diminished
capacity to enhance BCC proliferation
The role that leptin plays in the biology of obASCs and
their impact on BCCs was investigated through the
stable transfection of shRNA constructs targeting leptin
into lnASCs and obASCs. These cells were used to de-
termine the impact of silencing leptin on BCC prolifera-
tion. Leptin knockdown lnASCs and obASCs were
initially collected to demonstrate a reduction of lep-




Fig. 1 Adipose stromal/stem cells (ASCs) isolated from obese women (obASCs) enhance breast cancer cell (BCC) proliferation. a Estrogen
receptor positive BCCs were co-cultured (CC) with ASCs isolated from lean women (lnASCs) (n = 6 donors) or obASCs (n = 6 donors) for
7 days and FACS performed based on green fluorescent protein (GFP) expression. BCCs sorted by FACS were counted and data are
shown relative to the number of cells cultured alone. b RNA was collected from MCF7 cells, T47D cells, ZR75 cells, control short hairpin
RNA (control shRNA) lnASCs, and control shRNA obASCs and analyzed for aromatase expression by quantitative RT-PCR. Data were normal-
ized to the β-actin expression. c Conditioned media (CM) were collected from control shRNA lnASCs or control shRNA obASCs treated
with vehicle or letrozole. BCCs were cultured in the CM for 7 days and the number of GFP+ BCCs was counted. d CM were collected
from control shRNA lnASCs and control shRNA obASCs treated with vehicle or leptin neutralizing antibody. BCCs were cultured in the CM
for 7 days and the number of GFP+ BCCs was counted. Bar represents ± standard error of the mean. *P <0.05, **P <0.01, ***P <0.001,
relative to no co-culture BCCs; #P <0.05, ##P <0.01 between BCCs co-cultured with lnASCs and obASCs; ψψψP <0.001 relative to lnASCs
and obASCs; ΦΦΦP <0.001 between control shRNA obASCs treated with vehicle and leptin neutralizing antibody
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down efficiency was assessed with real-time RT-PCR
after purification of transfected cells with FACS. lnASCs
showed a reduction in leptin expression by 63.8 %, from
1.04-fold in control shRNA lnASCs to 0.37-fold in lep-
tin shRNA lnASCs, and obASCs demonstrated a reduc-
tion in leptin expression by 99.4 %, from 147.81-fold in
control shRNA obASCs to 0.85-fold in leptin shRNA
obASCs, respectively (P <0.05; Additional file 1). No
statistically significant difference was observed in thetranscript level of leptin between leptin shRNA lnASCs
and leptin shRNA obASCs. To characterize the cells,
lnASCs or obASCs transfected with the leptin shRNA or
control shRNA were differentiated in osteogenic differenti-
ation medium or adipogenic differentiation medium, plated
to determine colony forming unit capacity, and analyzed
for the expression of cell surface markers. Transfected
ASCs did not differ from non-transfected ASCs and main-
tained the ability to generate colony forming units and dif-
ferentiate into bone and fat (Additional file 1). The cells
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CD166 (while negative for the lymphohematopoietic
markers CD34 and CD45 and monocyte marker CD11b;
Additional file 1) similar to untransfected ASCs. The pro-
liferation rate of transfected ASCs did not differ from non-
transfected ASCs (Additional file 1), and no significant dif-
ference was observed between the proliferation rate of
lnASCs and obASCs transfected with control shRNAs or
leptin shRNAs (Additional file 1). The proliferative effects
of CM collected from control shRNA lnASCs, leptin
shRNA lnASCs, control shRNA obASCs, or leptin shRNA
obASCs was assessed in BCCs. CM collected from control
shRNA obASCs enhanced the number of BCCs, whereas
CM collected from leptin shRNA obASCs did not display
similar induction (Additional file 2).
The direct role of leptin secreted from obASCs on
BCC proliferation was investigated by co-culturing con-
trol shRNA lnASCs, leptin shRNA lnASCs, control
shRNA obASCs, or leptin shRNA obASCs with BCCs at
a 1:1 ratio. The proliferation of BCCs was compared to
BCCs cultured alone. MCF7, ZR75, and T47D cells dem-
onstrated an increase in the total cell number following
co-culture with control shRNA obASCs compared to
BCCs cultured alone or co-cultured with control lnASCs
(P <0.05; Fig. 2). The obASCs transfected with the leptin
shRNA were unable to induce proliferation of BCCs in
comparison to the obASC expressing the control
shRNA. Leptin shRNA obASCs reduced the extent of
proliferation in MCF7, ZR75, and T47D from 1.3E6 cells
to 0.5E6 cells (2.2-fold decrease), 1.2E6 cells to 0.3E6
cells (4.0-fold decrease), and 1.3E6 cells to 0.9E6 cells
(1.4-fold decrease), respectively, comparing BCCs ex-
posed to control shRNA obASCs to leptin shRNA
obASCs (P <0.05; Fig. 2). To assess whether CMFig. 2 Leptin is essential for the adipose stromal/stem cells isolated from o
Adipose stromal/stem cells isolated from lean women (lnASCs) and obASCs
leptin shRNA were co-cultured (CC) with BCCs. After 7 days, the green fluo
Bar represents ± standard error of the mean. *P <0.05, ***P <0.001, relative
control shRNA lnASCs and control shRNA obASCs; ΦΦΦP <0.001 for compar
shRNA obASCscollected from ASCs was able to induce BCC prolifera-
tion, CM was collected from control shRNA lnASCs,
leptin shRNA lnASCs, control shRNA obASCs, and lep-
tin shRNA obASCs. BCCs incubated in control shRNA
obASCs induced BCC proliferation by 1.4-fold in MCF7
cells, 1.8-fold in ZR75 cells, and 1.6-fold in T47D cells;
however BCCs incubated in control shRNA lnASCs, lep-
tin shRNA lnASCs, and leptin shRNA obASCs were un-
able to induce BCC proliferation. These results implicate
obASC-derived leptin as a key factor leading to en-
hanced proliferation of BCCs.
obASCs enhance BCC migration and invasion
BCCs were directly co-cultured for 7 days with lnASCs
or obASCs transfected with control shRNA or leptin
shRNA and collected by detection of GFP expression
using FACS. Sorted cells were re-suspended in serum-
free medium and plated on top of a transwell and
assessed for migration after 4 hours or plated on top of
a Matrigel-coated transwell and assessed for invasion
after 24 hours. The BCCs collected after co-culture dem-
onstrated enhanced migration towards chemoattractants
by at least 2.7-fold relative to non-co-cultured BCCs, fol-
lowing direct co-culture of BCCs with lnASCs or
obASCs (Fig. 3a). Silencing of leptin slightly diminished
the capacity of both lnASCs and obASCs, to affect BCC
migration; however, these results were not statistically
significant (Fig. 3a). The invasive capacity of BCCs was
enhanced after direct exposure to lnASCs and obASCs.
The impact of obASCs on BCC invasion was more ro-
bust than the effect of lnASC on BCC invasion. lnASCs
enhanced the invasion of MCF7, ZR75, and T47D cells
by 4.1 ± 1.1, 3.9 ± 0.8, and 3.8 ± 1.0 times, respectively,
while obASCs increased the invasive potential of MCF7,bese women (obASC)-driven breast cancer cell (BCC) proliferation.
transfected with either a control short hairpin RNA (control-shRNA) or
rescent protein-positive (GFP+) BCCs were sorted by FACS and counted.
to no co-culture; ##P <0.01, ###P <0.001 between BCCs co-cultured with
ison between BCCs co-cultured with control shRNA obASCs and leptin
BA
Fig. 3 Adipose stromal/stem cells isolated from obese women (obASC)-derived leptin increases invasion of breast cancer cells (BCCs). BCC cells were
co-cultured (CC) with adipose stromal/stem cells isolated from lean women (lnASCs) or obASCs stably transfected with a control short hairpin RNA
(control shRNA) or leptin shRNA (leptin shRNA) for 7 days. Green fluorescent protein-positive BCC cells were isolated with FACS and plated in the top
chamber of a, an uncoated 8-μm pore membrane, and assessed after 4 hours for migratory potential or b, a Matrigel-coated 8-μm pore membrane
and assessed after 24 hours for invasive capacity. Medium containing FBS was plated in the lower chamber and served as a chemoattractant. Data are
shown relative to cells without prior exposure to lnASCs or obASCs. Bar represents ± standard error of the mean: *P <0.05, ***P <0.001 relative to BCCs
cultured alone; ##P <0.01 for comparison between BCCs after co-culture with control shRNA lnASCs and control shRNA obASCs; ΦP <0.05, ΦΦP <0.01 be-
tween BCCs after co-culture with control shRNA obASCs and letpin shRNA obASCs
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times, respectively (P <0.05; Fig. 3b). Inhibiting leptin ex-
pression in obASCs significantly decreased the levels of
BCC invasion, while reducing leptin expression in
lnASCs did not have the same impact. Leptin inhibition
in obASCs reduced MCF7, ZR75, and T47D cell inva-
sion by 27.5 %, 29.3 %, and 28.1 %, respectively (P <0.05;
Fig. 3b). These results suggest that while obASCs have a
greater capacity to enhance the migration and invasion
of BCCs compared to lnASCs, obASC-derived leptin
only plays an integral role in BCC invasion.
Leptin shRNA obASCs reduce expression of proliferation
and epithelial-to-mesenchymal transition (EMT) genes
The mechanism(s) by which ASC-derived leptin affects
BCC signaling pathways was investigated using a custom
breast cancer PCR array to determine changes in the ex-
pression of previously identified cell cycle, apoptotic, and
angiogenic genes. Previously, our group showed alterationsin these genes in the MCF7 cells after co-culture with
obese ASCs [13]. Of the cell cycle, apoptotic, and angio-
genic genes assessed (CDKN2A, GSTP1, SFRP1, PLAU,
THBS1, CSF), none were significantly increased in the
three BCC lines following direct co-culture with obASCs
(Additional files 3, 4 and 5).
In contrast, investigation of EMT and metastatic
genes previously identified by us to be altered in
MCF7 cells after co-culturing with obASCs showed
uniform changes in all three BCC lines. Of the genes
assessed, BCCs overexpressed SERPINE1, IL-6, and
MMP-2 following direct co-culture with obASCs. Fur-
thermore, inhibition of leptin in obASCs diminished the
expression of these genes in BCCs (relative to obese ASCs;
P <0.05; Fig. 4; Additional files 3–5). No statistically signifi-
cant differences in gene expression were observed in BCCs
after co-culture with control shRNA lnASCs or leptin
shRNA lnASCs (Fig. 4; Additional files 3–5). SERPINE1 ex-
pression was significantly decreased in MCF7, ZR75, and
Fig. 4 Leptin inhibition reduces the expression of key regulatory genes involved in invasion and metastasis. Breast cancer cells (BCCs) were co-
cultured CC with adipose stromal/stem cells isolated from lean women (lnASCs) or adipose stromal/stem cells isolated from obese women
(obASCs) stably transfected with a control short hairpin RNA (control shRNA) or leptin shRNA. After 7 days, co-cultured cells were sorted by FACS
and BCCs were collected for total RNA extraction and cDNA synthesis. Genes involved in invasion and metastasis were assessed. Bar represents ±
standard error of the mean. *P <0.05, ***P <0.001 relative to BCCs cultured alone; ###P <0.01 for comparison between BCCs after co-culture with
control shRNA lnASCs and control shRNA obASCs; ΦΦΦP <0.001 for comparison between BCCs after co-culture with control shRNA obASCs and
leptin shRNA obASCs. MMP matrix metalloproteinase
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12.6-fold, respectively (P <0.05; Fig. 4; Additional files 3−5).
Additionally, leptin inhibition in obASCs limited the in-
duction of IL-6 expression in BCC by the obASCs, with
a 2.3-fold decrease in MCF7 cells, 2.0-fold decrease in
ZR75, and 1.5-fold decrease in T47D (P <0.05; Fig. 4;
Additional files 3–5). Moreover, inhibition of leptin in
obASCs resulted in a 27.4-fold, 179.2-fold, and 843.5-
fold decrease in MMP-2 expression in MCF7, ZR75, and
T47D cells, respectively (P <0.05; Additional files 3–5).
Together, these results indicate that obASCs increase the
mRNA expression of key metastatic genes in ER+ BCC
lines and suggest that obASCs may play a significant
role in EMT and metastasis.Leptin shRNA obASCs result in diminished tumorigenicity
and expression of EMT genes
In order to investigate the effects of leptin silencing on
tumorigenesis, MCF7 cells were implanted alone or mixed
with control shRNA obASCs or leptin shRNA obASCs into
the mammary fat pad of SCID/beige mice. After 36 days,
tumors formed with MCF7 cells mixed with leptin shRNA
obASCs were significantly smaller (1115.1 ± 36.7 mm3 and
1.22 ± 0.03 g) compared to tumors formed with MCF7 cells
mixed with control shRNA obASCs (2141.5 ± 29.5 mm3
and 1.92 ± 0.03 g) (P <0.001; Fig. 5a-c). Histological assess-
ment of the tumors confirmed that the bulk of the tumor
was composed of GFP expressing MCF7 cells (Fig. 5d). Fur-
thermore, immunohistochemical analysis confirmed the
A B
C D
Fig. 5 Leptin inhibition in adipose stromal/stem cells isolated from obese women (obASCs) reduces tumor volume. MCF7 cells were prepared
alone or co-injected with control short hairpin shRNA (control shRNA) obASCs or leptin shRNA obASCs (1:1 ratio) into the mammary fat pad of
SCID/beige mice (n = 5 mice/group). a Tumor volume was assessed every 3–4 days. b Representative tumors from each mouse (n = 5/group).
Scale bar represents 1 cm. c Tumor weight on day 36. d Representative images of H&E, green fluorescent protein (GFP) staining, and dsRed
staining of tumor sections visualized at × 10 and × 40 magnification (inset). Scale bar represents 50 μm. Bar represents ± standard error of the
mean. *P <0.001 relative to MCF7 xenografts; ΦP <0.001 for comparison between MCF7 plus control shRNA obASC xenografts and MCF7 plus
leptin shRNA obASC xenografts
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control shRNA obASCs mixed with MCF7 cells. In con-
trast, dsRed expression was not visible in tumors formed
with MCF7 alone or mixed with leptin shRNA obASCs
(Fig. 5d).
To assess the mechanism by which obASC-derived
leptin affects BCC signaling in vivo, RNA was isolated
from tumors and assessed with the custom breast cancer
PCR array (Additional file 6). Assessment of the tumors
showed increased expression of SERPINE1, MMP-2, and
IL-6 in tumors formed with control shRNA obASCs
mixed with leptin (P <0.05; Fig. 6a; Additional file 6). In-
hibition of leptin in obASCs negated the gene induction
of SERPINE1 and MMP-2 caused by obASCs in tumors.
Western blot analysis was conducted on tumor samples to
validate the expression of SERPINE1 and MMP-2 proteins.
Tumors formed with MCF7 cells mixed with control
shRNA obASCs demonstrated a 3.0-fold (±0.5) induction
of SERPINE1 while tumors formed with MCF7 cells mixedwith leptin shRNA obASCs demonstrated a 1.6-fold
(±0.1) increase in SERPINE1, relative to MCF7 cells un-
exposed to ASCs (Fig. 6c). Likewise, tumors formed
with MCF7 cells mixed with control shRNA obASCs
demonstrated a 4.5-fold (±0.2) increase in MMP-2.
Meanwhile, tumors formed with MCF7 cells mixed with
leptin shRNA obASCs showed no difference from
MCF7 cells without prior exposure to ASCs (Fig. 6c).
Confirmation by immunohistochemical analysis demon-
strated increased expression of SERPINE1 and MMP-2
in tumors formed with MCF7 cells and control shRNA
ASCs compared to tumors formed with MCF7 cells and
leptin shRNA ASCs (Fig. 6d).
Leptin inhibition reduces obASC-induced metastasis of
BCCs
As obASCs enhance the expression of EMT and meta-
static genes in vitro, the role obASCs play in EMT
and metastasis of BCCs was assessed in vivo.
A B
C D
Fig. 6 Adipose stromal/stem cells isolated from obese women (obASC)-derived leptin induces SERPINE1 and matrix metalloproteinase-2 (MMP2)
expression in MCF7 xenografts. MCF7 cells were prepared alone or co-injected with control short hairpin RNA (control shRNA) obASCs or leptin
shRNA obASCs (1:1 ratio) into the mammary fat pad of SCID/beige mice (n = 5 mice/group). After 36 days, tumors were harvested for analysis.
a Total cellular RNA was isolated from tumors and analyzed for the expression of SERPINE1, MMP-2, and IL-6. b Western blot analysis of tumor
lysate. A total of 20 μg of protein was separated by SDS-PAGE under reducing conditions, blotted, and probed with indicated antibodies. Blots
were stripped and probed with actin antibody for normalization. c Densitometry analysis of SERPINE1 and MMP2 bands, normalized to actin.
d Representative images of SERPINE1 staining and MMP-2 staining of tumor sections visualized at × 10 and × 40 magnification (inset). Scale
bar represents 50 μm. Bar represents ± SD. *P <0.05, **P <0.01, ***P <0.0001 relative to MCF7 xenografts; ΦP <0.05, ΦΦP <0.01, ΦΦΦP <0.0001
between MCF7 plus control shRNA obASC xenografts and MCF7 plus leptin shRNA obASC xenografts
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cells alone, MCF7 cells mixed with lnASCs, or with
obASCs for 36 days. Metastatic lesions in the lung and
liver were visualized by H&E staining and quantified.
Mice implanted with MCF7 cells alone had no meta-
static lesions, whereas mice injected with MCF7 cells
mixed with lnASCs (0.8 ± 0.07 %) and mice injected
with MCF7 cells mixed with obASCs (2.0 ± 0.09 %) had
significantly greater numbers of metastatic lesions (P
<0.05; Fig. 7a-b; Additional file 7). These results indicate
that while both lnASCs and obASCs enhanced metasta-
sis of MCF7 cells, obASCs induced metastasis to the
lung and liver more efficiently compared to lnASCs.
The effects of inhibiting obASC-derived leptin on EMT
and metastasis were investigated in vivo. SCID/beige mice
were implanted with MCF7 cells alone, MCF7 cells mixed
with control shRNA obASCs, or MCF7 cells mixed with
leptin shRNA obASCs for 36 days. Metastasis to the lung
and liver was visualized by H&E staining and quantified.
Mice injected with MCF7 cells mixed with control shRNA
obASCs (2.0 ± 0.20 %) had significantly more metastasis
compared to mice injected with MCF7 cells mixed with
leptin shRNA obASCs (0.5 ± 0.04 %) (P <0.05; Fig. 7c-d;
Additional file 7). These results suggest that obASCs-derived leptin drives metastasis of MCF7 cells in the lung
and liver.
Discussion
The incidence of obesity has been steadily increasing
over the past few decades. Obese and overweight indi-
viduals now account for more than two thirds of the
adult population in the USA [18]. Much co-morbidity is
associated with obesity, and a clear epidemiological asso-
ciation between obesity and the prevalence of numerous
cancers has been established; one being breast cancer
[19]. While the relative risk amongst studies varies from
1.5 to 2.5, there is consensus that there is an increased
relative risk of breast cancer development in women
with BMI >30 [20–22].
Recent studies investigating the role of adipose tissue
on breast cancer, in particular the excessive accumula-
tion of adipose tissue in obesity, implicate ASCs as a sig-
nificant factor contributing to disease development [23].
ASCs are stromal/stem progenitor cells of mesenchymal
origin and have been shown to travel through the blood
to distant tumor sites where they differentiate into vas-
cular pericytes or secrete growth factors that support the
tumor microenvironment [24, 25]. Additional studies
A B
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Fig. 7 Leptin is essential for the adipose stromal/stem cells isolated from obese women (obASC)-driven metastasis MCF7 cells in vivo. a MCF7
cells were prepared alone or co-injected with adipose stromal/stem cells isolated from lean women (lnASCs) or obASCs (1:1 ratio) or c, co-injected
with control short hairpin RNA (control shRNA) obASCs or leptin shRNA obASCs into the mammary fat pad of SCID/beige mice (n = 5 mice/
group). Primary tumors were allowed to expand for 36 days, and the lung and liver were harvested for histological analysis of metastasis. Metastasis
index was determined by the percentage of the liver and lung occupied by metastatic lesions. b, d Representative images of liver and lung sections.
Liver sections were visualized at × 40 magnification and lung sections were visualized at × 10 and × 40 magnification (inset). Scale bars represent 50
μm. Bar represents ± standard error of the mean. ***P <0.0001 relative to MCF7 xenografts; ###P <0.0001 for comparison between MCF7 plus lnASC
xenografts and MCF7 plus obASC xenografts; ΦΦΦP <0.0001 for comparison between MCF7 plus control shRNA obASC xenografts and MCF7 plus leptin
shRNA obASC xenografts. Arrows highlight metastatic lesions within the liver or lung
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have the potential to traffic to the tumor and promote
tumor progression through the secretion of proteases
and pro-angiogenic factors [15, 26]. In the present study,
the impact of obASCs on several BCC lines was investi-
gated. The data presented here indicate that obASCs en-
hance the proliferation of ER+ BCCs and the preferential
impact of obASC on ER+ BCC lines suggest that ER+
BCCs are able to respond to factors produced by the
obASCs, which are not produced by lnASCs. Further-
more, the data suggests that TNBC may not express re-
ceptors or that their signaling pathways do not respond
to the factors produced by obASCs.
Previously, ASCs have been shown to be a source of
the leptin in the adipose tissue, and this leptin produced
by the ASCs has been shown to stimulate BCC prolifera-
tion [13]. Leptin, a growth factor produced within adi-
pose tissue, primarily functions to maintain energy
balance. It also plays an important role in cell growth
and differentiation under normal physiological condi-
tions [27]. Previous studies have also indicated that a
leptin-leptin receptor signaling axis may crosstalk with
the ER and enhance tumorigenesis and metastasis [28–31].
These findings are consistent with our current report ofobASCs and their preferential role in increasing ER+ BCCs
but not ER− BCCs.
Obesity has been shown to result in hyperleptinemia
[32]. Hyperleptinemia leads to an increase in breast can-
cer cell proliferation, migration, and invasion, which
gives rise to more aggressive and metastatic tumor cells
[33–41]. Several laboratories have confirmed that ex-
ogenously delivered leptin increases BCC proliferation
at different concentrations (100–1,600 ng/ml) [33–40].
Previously, studies have shown that the mechanism
by which leptin promotes the survival of cancer cells
is through the activation of multiple signaling path-
ways, such as those involving mitogen-activated pro-
tein kinase (MAPK), Janus kinase 2-signal transducer
and activator of transcription 3 (JAK2-STAT3) and
phosphatidylinositol 3-kinase-protein kinase B (PI3K-
AKT) [42, 43]. However, additional studies are neces-
sary to determine the sources of leptin in the adipose
tissue and whether leptin secreted by the obASCs uti-
lizes similar signal transduction pathways to promote
the survival of cancer cells.
The mechanism by which obASC-derived leptin
promotes alterations to the biology of BCCs was in-
vestigated by inhibiting leptin expression by stably
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construct. The data suggest that obASC-derived leptin
enhances several central processes such as prolifera-
tion and metastasis of cancer cells that ultimately en-
hance the aggressiveness of breast cancer cells.
However, the precise mechanism by which obASC-
derived leptin enhances proliferation remains to be
determined. Our assessment of several key prolifera-
tive factors demonstrated increased expression of
CDKN2A and SFRP1 in MCF7 and ZR75 cells follow-
ing co-culture with obASCs. Inhibiting leptin expres-
sion negated the increased expression of CDKN2A
and SFRP1 in MCF7 and ZR75 cells even after co-
culture, suggesting that the expression of these two
genes are leptin-mediated; however, these results did
not translate into the T47D cells, which indicate
obASC is not signaling through CDKN2A and SFRP1
to increase the proliferation of T47D cells. Therefore,
additional analysis utilizing RNA-sequencing or other
global approaches to assess gene expression may be
warranted in order to assess the broader impact of
obASCs and obASC-derived leptin on the prolifera-
tion of all ER+ BCCs.
With respect to migration and invasion, obASCs
enhanced migration and invasion of BCCs. However,
inhibition of leptin only reduced the invasive potential
of BCCs. These results suggest that while other fac-
tors secreted by obASCs enhance BCC migration, lep-
tin plays an important role in BCC invasion. Studies
have shown that migration is largely dependent on
integrins and adhesion molecules, while invasion is
dependent on the expression of proteases [44, 45].
Therefore, obASC-secreted leptin likely regulates the
expression of proteases.
With respect to metastasis, leptin appears to signal
primarily through SERPINE1 and MMP-2 [46, 47]. SER-
PINE1, a serine protease inhibitor, limits the activity of
matrix metalloproteases in the extracellular matrix
microenvironment [48]. Paradoxically, SERPINE1 is also
involved in other molecular interactions, including bind-
ing to the extracellular matrix protein vitronectin and
endocytosis receptors of the low-density lipoprotein re-
ceptor (LRP) family. Binding of SERPINE1 to vitronectin
results in detachment of the tumor cell from the extra-
cellular matrix (ECM), leading to enhanced mobility of
the cells [49]. Likewise, MMP-2 expression correlates
with increased metastasis and poorer clinical prognosis
[50, 51]. Furthermore, the cells expressing MMP-2 are
also important and indicative of the aggressiveness of
the breast cancer [52]. Elevated expression of MMP-2 in
cancer cells has been found to be associated with smaller
tumors, while expression of MMP-2 by stromal cells has
been associated with increased aggressiveness [52]. Fur-
thermore, expression of IL-6 was similarly upregulatedin BCCs following co-culture with obASCs. However, tu-
mors formed with a mixture of leptin shRNA obASCs
and BCCs did not demonstrate similar reduction in IL-6,
which suggests that other cells within the tumor micro-
environment may be contributing to the increase in IL-
6. In particular, studies have shown that immune cells
express high levels of IL-6 during the cancer progression
[53, 54]. Nevertheless, the elevated expression of SER-
PINE1 and MMP-2 correlated with the increased inci-
dence of metastatic lesions in the lung and liver of mice
injected with a mixture of obASCs and cancer cells,
compared to mice that received cancer cells alone or
cancer cells mixed with lnASCs. Furthermore, the ex-
pression of SERPINE1 and MMP-2 was reduced in tu-
mors formed with cancer cells and leptin shRNA
obASCs, relative to tumors formed with cancer cells and
control shRNA obASCs. These results suggest that lep-
tin affects the overexpression of these key metastatic fac-
tors within the tumor.
Conclusion
obASCs not only contribute to the primary tumor
growth, but these cells also enhance metastasis through
a leptin-mediated pathway(s) involving SERPINE1 and
MMP-2. The data suggest that the ASCs, which are in
close proximity to the cancer cells within a tumor, are a
novel avenue by which obesity influences the biology of
cancer cells. Additional studies investigating the cells
that contribute to the tumor microenvironment and
their interaction with the cancer cells in obese patients
are necessary to provide additional targets that will de-
lineate the development and progress of breast cancer in
these patients. With respect to leptin, the results of these
studies would suggest that in obese individuals leptin is
a primary molecule driving changes in the BCC that re-
sult in enhanced tumorigenicity and metastasis.
Additional files
Additional file 1: Adipose stromal/stem cells (ASCs) isolated from
lean women (lnASCs) and ASCs isolated from obese women
(obASCs) were stably transfected with control short hairpin RNA
(ctrl-shRNA) and leptin shRNA (lep-shRNA). lnASCs (n = 6 donors) and
obASCs (n = 6 donors) were transfected with a ctrl-shRNA construct
targeting a non-human gene or a lep-shRNA construct targeting leptin.
Cells underwent antibiotic selection, followed by FACS. ASCs stably
transfected with the shRNA vectors were assessed with real-time
polymerase chain reaction to quantitative leptin expression at the
RNA level (A). B Stably transfected ASCs were characterized by self-renewal
capacity demonstrated by colony forming unit assay. Cells seeded at low
density were assessed after 14 days by staining with crystal violet. C Stably
transfected ASCs were plated in 6-well dishes and exposed to bone
differentiation medium and fat differentiation medium to determine
their ability to undergo adipogenic and osteogenic differentiation.
After 21 days, cells were fixed and stained with Oil Red O or Alizarin
Red for adipogenic differentiation and osteogenic differentiation, respectively.
Representative images of ASCs acquired at × 10 (adipogenic differentiation)
and × 4 (osteogenic differentiation) are shown. D Stably transfected cells
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markers. E The proliferation rate of lnASCs and obASCs were compared with
stably transfected control shRNA lnASCs and control shRNA obASCs. F The
proliferative rate of stably transfected control shRNA and leptin shRNA lnASCs
and obASCs were compared. Bar is ± SD. ***P <0.001 for comparison of
ctrl-shRNA lnASC and ctrl-shRNA obASCs, ###P <0.001 for comparison of
ctrl-shRNA obASCs and lep-shRNA obASCs (TIFF 6836 kb)
Additional file 2: Leptin in conditioned media is essential for the
adipose stromal/stem cells (ASCs) isolated from obese women
(obASC)-driven breast cancer cell (BCC) proliferation. Conditioned media
(CM) were collected from control short hairpin RNA (shRNA) ASCs isolated
from lean women (lnASCs), leptin shRNA lnASCs, control shRNA obASCs, and
leptin shRNA obASCs. BCCs were cultured in the CM for 7 days and the
number of GFP+ BCCs was counted. *P <0.05; **P <0.01 relative to
unconditioned cells; ΦΦΦP <0.001 for comparison between control shRNA
obASCs and leptin shRNA obASCs (TIFF 3589 kb)
Additional file 3: mRNA expression of MCF7 cells after exposure to
leptin (lep) knockdown adipose stromal/stem cells (ASCs). Data are
shown as fold change relative to the respective breast cancer cell line
without previous co-culture with ASCs. *P <0.05; #P <0.01; ¥P <0.001. EMT
epithelial-to-mesenchymal transition, lnASCs, adipose stromal/stem cells
isolated from lean women, obASCs adipose stromal/stem cells isolated
from obese women (PDF 50 kb)
Additional file 4: mRNA expression of ZR75 cells after exposure to
leptin knockdown adipose stromal/stem cells (ASCs). Data are shown
as fold change relative to respective breast cancer cell line without
previous co-culture with ASCs. *P <0.05; #P <0.01; ¥P <0.001. lep leptin, ctrl
control, lnASCs, adipose stromal/stem cells isolated from lean women,
obASCs adipose stromal/stem cells isolated from obese women, EMT
epithelial-to-mesenchymal transition (PDF 50 kb)
Additional file 5: mRNA expression of T47D cells after exposure to
leptin knockdown adipose stromal/stem cells (ASCs). Data are
shown as fold change relative to respective breast cancer cell line
without previous co-culture with ASCs. *P <0.05; #P <0.01; ¥P <0.001.
lep leptin, ctrl control, lnASCs, adipose stromal/stem cells isolated
from lean women, obASCs adipose stromal/stem cells isolated from
obese women, EMT epithelial-to-mesenchymal transition (PDF 50 kb)
Additional file 6: mRNA expression of xenografts formed with
MCF7 cells and leptin knockdown adipose stromal/stem cells
(ASCs). Data are shown as fold change relative to respective breast
cancer cell line without previous co-culture with ASCs. *P <0.05; #P <0.05;
¥P <0.05. lep leptin, ctrl control, lnASCs, adipose stromal/stem cells isolated
from lean women, obASCs adipose stromal/stem cells isolated from obese
women, EMT epithelial-to-mesenchymal transition (PDF 49 kb)
Additional file 7: Adipose stromal/stem (ASCs) cells isolated from
obese women (obASCs) enhance metastasis of breast cancer cells.
A MCF7 cells were prepared alone or co-injected with adipose stromal/
stem cells isolated from lean women (lnASCs) or obASCs (1:1 ratio), or B
co-injected with control short hairpin RNA (ctrl-shRNA) obASCs or leptin
short hairpin RNA (lep-shRNA) obASCs into the mammary fat pad of SCID/
beige mice (n = 5 mice/group). After 36 days, tissues were harvested for
histological analysis of metastasis. Representative histological images of
liver sections with and without highlighted metastatic cells are shown.
Images were acquired at × 2 magnification. (TIFF 6938 kb)Abbreviations
AKT: kinase-protein kinase B; ASC: adipose stromal/stem cell; BCC: breast
cancer cell; BMI: body mass index; BSA: bovine serum albumin;
CCM: complete culture medium; CDKN2A: cyclin-dependent kinase inhibitor
2A; CFU: colony-forming unit; CM: conditioned media; CSF1: colony
stimulating factor 1; DAB: 3,3′-Diaminobenzidine; DMEM: Dulbecco’s
modified Eagle’s medium; EMT: epithelial-to-mesenchymal transition;
ER+: estrogen receptor positive; FACS: fluorescence-activated cell sorting;
FFPE: formalin-fixed, paraffin-embedded; GFP: green fluorescent protein;
GSTP1: glutathione S-transferase pi 1; H&E: hematoxylin and eosin;
HRP: horseradish peroxidase; IL-6: interleukin 6; JAK2: Janus kinase 2; leptin
shRNA lnASCs: adipose stromal/stem cells isolated from lean women
transfected with leptin short hairpin RNA; leptin shRNA obASCs: adiposestromal/stem cells isolated from obese women transfected with leptin short
hairpin RNA; lnASCs: adipose stromal/stem cells isolated from lean women;
LRP: low-density lipoprotein receptor; MAPK: mitogen-activated protein
kinase; MMP-2: matrix metalloproteinase-2; obASCs: adipose stromal/stem
cells isolated from obese women; PBS: phosphate-buffered saline;
PI3K: phosphatidylinositol 3; PLAU: plasminogen activator, urokinase;
qRT-PCR: quantitative reverse transcriptase polymerase chain reaction;
SEM: standard error of the mean; SERPINE1: plasminogen activator
inhibitor-1; SFRP1: secreted frizzled-related protein 1; shRNA: short hairpin
RNA; SM: stromal medium; STAT3: signal transducer and activator of
transcription 3; THBS1: thrombospondin 1; TNBC: triple-negative breast
cancer; TNT: Tris-NaCl-Tween buffer.
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